Drugs & TargetsFreeTCCL Archive European Commission Approves Subcutaneous Rituximab The European Commission approved a subcutaneous formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma.March 31, 2014Vol.37 No.03